Gaush Meditech

Gaush Meditech Net Margin

The Net Profit Margin of Gaush Meditech (2407.HK) as of Nov 2, 2026 is 6.97 %. In the previous year, Net Profit Margin was 6.47 % — a change of 7.73% (higher).

Net Margin

6.97 %

YoY

7.73%

Last updated:

Net Profit Margin of Gaush Meditech is 2025 6.97 % . Net Profit Margin of Gaush Meditech was 2024 6.47 % . It decreases by 7.73% higher compared to the previous year.

Gaush Meditech's net margin stands at 7.0%, up from -14.7% several years earlier.

The Gaush Meditech Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-3.35 CNY
Jan 1, 2020
10.33 CNY
Jan 1, 2021
-14.67 CNY
Jan 1, 2022
-27.89 CNY
Jan 1, 2023
12.34 CNY
Jan 1, 2024
6.47 CNY
Jan 1, 2025
6.97 CNY
The Gaush Meditech Net Margin history
YEARNet MarginYoY
6.97 %+7.73%
6.47 %-47.58%
12.34 %-144.25%
-27.89 %+90.08%
-14.67 %-242.03%
10.33 %-408.58%
-3.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gaush Meditech Stock analysis

What does Gaush Meditech do? Gaush Meditech Ltd. generates revenue through four business segments. The Proprietary Products segment develops and sells surgical equipment, intraocular lenses, and diagnostic and treatment devices for ophthalmic diseases, along with related software and consumables. The Distribution segment distributes branded ophthalmic medical devices and consumables. The Technical Services segment offers after-sales services including warranty, maintenance, and consumables support. The Others segment handles equipment leasing and intellectual property agency services. Products are used in treating conditions like cataracts, glaucoma, and pediatric ophthalmology across various medical specialties. The company's primary customers include hospitals, clinics, and medical institutions specializing in ophthalmology. These institutions purchase proprietary devices, branded consumables, and technical support services. The firm's focus on ophthalmic subspecialties ensures consistent demand for its products and services in the treatment of eye diseases. Revenue streams are diversified across product development, distribution, and post-sale services. The proprietary segment drives innovation with surgical equipment and lenses, while distribution and technical services provide steady income from established medical partners. Equipment leasing and IP services in the Others segment contribute to additional revenue without requiring direct product sales. Gaush Meditech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gaush Meditech stock

Net Profit Margin of Gaush Meditech is 6.97 % in 2025.

Net Profit Margin of Gaush Meditech changed from 6.47 % to 6.97 %, representing a 7.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Gaush Meditech since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Gaush Meditech with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Gaush Meditech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Gaush Meditech